← Back to Search

Electrolyte Supplement

Potassium + Water for High Blood Pressure (PHACKs Trial)

N/A

Recruiting

Research Sponsored by Auburn University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Between the ages of 18-30 years

BMI below 35 kg/m2

Must not have

Have any precluding medical conditions (i.e. hemophilia) or medication (Pradaxa, Eliquis, etc.) that prevent participants from giving blood

Take any of the following medications that are contraindicated with potassium supplementation: Renin-angiotensin-aldosterone system (RAAS) blockers (Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan), Non-steroidal anti-inflammatory medications (Aspirin, Ibuprofen, Naproxen), Non-selective beta-blockers (Pindolol, Penbutolol, Oxprenolol, Propranolol, Nadolol, Sotalol, Timolol, Tertatolol), Calcineurin inhibitors (Cyclosporine), Heparin (or other blood thinning medications)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre-intervention (14 days)

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to investigate if adding a potassium supplement to water can improve hydration and cardiovascular health in young Black and White adults. Black adults are at a higher risk of cardiovascular disease and kidney disease due to

Who is the study for?

This trial is for young adults aged 18-30 with a BMI below 35, who don't have metabolic diseases like diabetes, kidney or lung issues, cardiovascular conditions, autoimmune disorders, or a history of cancer. They should also have a resting blood pressure no higher than 150/90 mmHg.

What is being tested?

The study tests if drinking water with added potassium (2000mg/day) can improve hydration and heart health better in Black adults compared to White adults. It involves taking urine and blood samples before and after a two-week period of this hydration strategy.

What are the potential side effects?

Possible side effects from high potassium intake include stomach discomfort, nausea, diarrhea or constipation. Overconsumption might lead to hyperkalemia which affects heart rhythm but is unlikely at the dose given.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 30 years old.

Select...

My BMI is under 35.

Select...

I do not have diabetes, kidney, lung, heart diseases, autoimmune conditions, or a history of cancer.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not have conditions like hemophilia or take medications like Pradaxa that prevent blood donation.

Select...

I am not taking any medication that is unsafe with potassium supplements.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre-intervention (14 days)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre-intervention (14 days)

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-intervention (14 days) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

24-hour ambulatory blood pressure

Brachial blood pressure

Plasma copeptin

+5 more

Secondary study objectives

Blood glucose

Dietary intake

Inflammatory cytokine responses

+8 more

Other study objectives

Area deprivation index

Blood pressure reactivity responses

Hematocrit

+2 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Water and PotassiumExperimental Treatment1 Intervention

N=40, 20 males, 20 females. Following the two-week habitual run-in period, this group will receive 2000mg potassium supplementation/day for 14 days. This will be achieved by taking capsules filled with potassium citrate powder.

Group II: Habitual consumptionActive Control1 Intervention

N=40, 20 males, 20 females. All participants will be monitored after two weeks of habitual water and potassium prior to being assigned into two weeks of water and potassium.

0 / 5Eligibility criteria met